Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin

International Journal of Antimicrobial Agents

Volumn 27, Issue 5, 2006, Pages 439-443

  Steward, J ^a   Piercy, T ^a   Lever, M S ^a   Simpson, A J H ^a,b   Brooks, T J G ^a,c  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Aerosol; Francisella tularensis; Mouse model; Quinolones

Indexed keywords

CIPROFLOXACIN; DEXAMETHASONE; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FRANCISELLA TULARENSIS; MORTALITY; MOUSE; NONHUMAN; PNEUMONIC TULAREMIA; PRIORITY JOURNAL; PROVOCATION TEST; RELAPSE; TREATMENT OUTCOME; TULAREMIA; ANIMAL; BACTERIAL PNEUMONIA; BAGG ALBINO MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; FEMALE; FLUOROQUINOLONES; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; QUINOLINES; TULAREMIA;

EID: 33646157745     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.02.006     Document Type: Article

References (28)

1. Butler T. Plague and tularemia. Pediatr Clin North Am 26 (1979) 355-366
2. Dennis D.T., Inglesby T.V., Henderson D.A., et al. Tularemia as a biological weapon: medical and public health management. JAMA 285 (2001) 2763-2773
3. Conlan J.W., Chen W., Shen H., Webb A., and KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 34 (2003) 239-248
4. Enderlin G., Morales L., Jacobs R.F., and Cross J.T. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 19 (1994) 42-47
5. Evans M.E., Gregory D.W., Schaffner W., and McGee Z.A. Tularemia: a 30-year experience with 88 cases. Medicine 64 (1985) 251-269
6. Health Protection Agency. Interim guidelines for action in the event of a deliberate release: Tularaemia, 25 January 2006, version 2.0. London: HPA. Available at: www.hpa.org.uk/infections/topics_az/deliberate_release/Tularaemia/PDFs/tularaemia_guidelines.pdf [accessed 15 February 2006].
7. Mason W.L., Eigelsbach H.T., Little S.F., and Bates J.H. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis 121 (1980) 39-45
8. Russell P., Eley S.E., Fulop M.J., Bell D.L., and Titball R.W. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J Antimicrob Chemother 41 (1998) 461-465
9. Sawyer W.D., Dangerfield H.G., Hogge A.L., and Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev 30 (1966) 542-548
10. Arav-Boger R. Cat-bite tularemia in a seventeen-year-old girl treated with ciprofloxacin. Pediatr Infect Dis J 19 (2000) 583-584
11. Scheel O., Reiersen R., and Hoel T. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis 11 (1992) 447-448
12. Darling R.G., Catlett C.L., Huebner K.D., and Jarrett D.G. Threats in bioterrorism. I: CDC category A agents. Emerg Med Clin North Am 20 (2002) 273-309
13. Steward J., Lever M.S., Simpson A.J.H., Sefton A.M., and Brooks T.J.G. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother 54 (2004) 95-99
14. Steward J., Lever M.S., Russell P., et al. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. Int J Antimicrob Agents 24 (2004) 609-612
15. Druett H.A. A mobile form of the Henderson apparatus. J Hyg (Cambridge) 67 (1969) 37-48
16. Petrie A., and Watson P. Statistics for veterinary and animal science (2000), Blackwell Science, London, UK
17. Guyton A.C. Measurement of the respiratory volumes of laboratory animals. Am J Physiol 150 (1947) 70-77
18. Ikäheimo I., Syrjälä H., Karhukorpi J., Schildt R., and Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 46 (2000) 287-290
19. Limaye A.P., and Hooper C.J. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 29 (1999) 922-924
20. Syrjälä H., Schildt R., and Räisäinen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 19 (1991) 68-71
21. Chocarro A., Gonzalez A., and Garcia I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis 31 (2000) 623
22. Johansson A., Berglund L., Sjöstedt A., and Tarnvik A. Ciprofloxacin for treatment of tularemia. Clin Infect Dis 33 (2001) 267-268
23. Morris T.H. Antibiotic therapeutics in laboratory animals. Lab Anim 29 (1995) 16-36
24. Bristol-Myers Squibb. Gatifloxacin package insert (2000), Bristol-Myers Squibb, Princeton, NJ
25. Ji B., Lounis N., Maslo C., Truffot-Pernot C., Bonnafous P., and Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42 (1998) 2066-2069
26. Miyazaki E., Miyazaki M., Chen J.M., Chaisson R.E., and Bishai W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43 (1999) 85-89
27. Jacobs R.F. Tularemia. Adv Pediatr Infect Dis 12 (1996) 55-69
28. McCrumb F.R. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev 25 (1961) 262-267